• Publications
  • Influence
Human Umbilical Cord Matrix Stem Cells: Preliminary Characterization and Effect of Transplantation in a Rodent Model of Parkinson's Disease
The umbilical cord matrix appears to be a rich, noncontroversial, and inexhaustible source of primitive mesenchymal stem cells.
Matrix Cells from Wharton's Jelly Form Neurons and Glia
Cells from the matrix of umbilical cord have properties of stem cells and may, thus, be a rich source of primitive cells, and their capacity to differentiate into a neural phenotype in vitro is shown.
Concise Review: Wharton's Jelly‐Derived Cells Are a Primitive Stromal Cell Population
It is suggested that WJCs are a primitive stromal cell population with therapeutic potential and further work is needed to determine whether WJcs engraft long‐term and display self‐renewal and multipotency in vivo and, as such, demonstrate whether Wharton's jelly cells are a true stem cell population.
Immune Properties of Human Umbilical Cord Wharton's Jelly‐Derived Cells
The results indicate that human UCMS cells inhibit splenocyte proliferation response to concanavalin A stimulation, that they do not stimulate T‐cell proliferation in a one‐way MLR, and that they inhibit the proliferation of stimulated T cells in a two‐ way MLR.
Expression of early transcription factors Oct-4, Sox-2 and Nanog by porcine umbilical cord (PUC) matrix cells
The presence of Nanog, Oct-4 and Sox-2 transcription factors, along with the other characteristics of PUC cells such as their colony-forming ability, Hoechst dye-excluding side population and alkaline phosphatase expression, suggests that P UC cells have properties of primitive pluripotent stem cells.
Stem cells in the umbilical cord
This review will focus on the umbilical cord-derived stem cells and compare those cells with adult bone marrow-derived mesenchymal stem cells.
Rat umbilical cord stem cells completely abolish rat mammary carcinomas with no evidence of metastasis or recurrence 100 days post-tumor cell inoculation.
Unmodified human UCMS cells could be used for targeted cytotherapy for breast cancer by showing complete regression of tumors to undetectable levels by 34 to 38 days with no evidence of metastasis or recurrence 100 days post-tumor cell inoculation.
Wharton's Jelly Stem Cells as Agents for Cancer Therapy
Stem cell based therapy has significant potential to treat various diseases including primary and metastatic cancers. The umbilical cord matrix stem cells (UCMSC) derived from human umbilical cord